Stockreport

FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study

BeyondSpring, Inc. - Ordinary Shares  (BYSI) 
Last beyondspring, inc. - ordinary shares earnings: 4/30 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.beyondspringpharma.com
PDF NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a New York-based global biopharmaceutical company focu [Read more]